Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Pomalidomide, an immunomodulatory agent, has structural and mechanistic properties that are similar to those of lenalidomide, but it may also elicit distinct biologic effects. 13,14 Pomalidomide ...

Similarly, isatuximab, pomalidomide, dexamethasone was compared to pomalidomide and dexamethasone. Under 10% of these patients were not lenalidomide-refractory, so the majority of these patients ...

Pomalidomide is an oral IMiD immunomodulatory agent with significant activity in RRMM. 9 With direct tumoricidal, potent immune-activating, antiangiogenic and anti-inflammatory activities ...

Pomalidomide offers therapeutic benefits in patients with lenalidomide-resistant multiple myeloma, but the reasons for its efficacy in such patients are sadly shrouded in mystery.

We conducted a randomized, placebo-controlled trial to evaluate the safety and efficacy of pomalidomide for the treatment of HHT. We randomly assigned patients, in a 2:1 ratio, to receive ...

Pomalidomide, a cancer medication, has been revealed in a clinical trial to be safe and efficacious in treating hereditary hemorrhagic telangiectasia (HHT).This rare bleeding disorder affects more ...

You take pomalidomide as capsules with a glass of water. You need to swallow the capsules whole. Don’t break or chew them. You should take them at the same time every day. You can take pomalidomide ...

A new editorial was published in Oncoscience's Volume 12 on January 14, 2025, titled "Pomalidomide improved immune profiles in myeloma.". The editorial by researchers Hannah Seah, Vaishnavi Reddy ...

Significant reduction seen in epistaxis severity with pomalidomide treatment for patients with HHT. HealthDay News — For patients with hereditary hemorrhagic telangiectasia (HHT), pomalidomide ...